✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
LCL161 is an investigational drug.
There have been 10 clinical trials for LCL161. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2013.
The most common disease conditions in clinical trials are Neoplasms, Neoplasms, Plasma Cell, and Lung Neoplasms. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and Delta Clinical Research, LLC.
Recent Clinical Trials for LCL161
|Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma||Novartis Pharmaceuticals||Phase 1|
|A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat||Novartis Pharmaceuticals||Phase 1|
|LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies||Novartis Pharmaceuticals||Phase 1/Phase 2|